

A Biomathematical Approach to Tumour Growth Prediction: Computational Modelling and Parameter Estimation

Elena Grace¹

¹University West, Sweden

ABSTRACT

The growth of a tumour is a complex biological process driven by cell proliferation, nutrient supply, and interactions with the microenvironment. Accurate forecasting of tumor development is essential for early detection, treatment planning, and the customization of cancer treatment. The article presents a biomathematical method for predicting tumour growth based on computational modelling and parameter estimation. Tumour dynamics over time are represented using mathematical models, particularly growth models based on ordinary differential equations, such as exponential, logistic, and Gompertz formulations. Such models are coupled with computational simulations to study the growth behavior of various biological conditions. Experimental and clinical data are used to estimate parameters and determine essential growth parameters, including the tumor proliferation rate and carrying capacity, so that the models reflect real tumor behaviour. Estimation errors are minimized, and model reliability is maximized through optimization and numerical techniques. The performance of each model is evaluated by comparing simulated tumour growth curves with observed data, enabling assessment of the model's predictive accuracy and applicability. Results have demonstrated that, when combined with sound parameter estimation methods, bio-mathematical models can effectively elucidate tumour growth trends and provide useful predictions. The present strategy highlights the potential of computational modelling in oncology to gain insights into tumor dynamics, to inform treatment decisions, and to guide the design of tailored therapeutic approaches for patients.

ARTICLE HISTORY

Received November 11, 2025

Accepted January 08, 2026

KEYWORDS

Biomathematical Approach (BMA),

Tumour Growth Prediction (TGP),

Computational Modelling (CM), Parameter Estimation (PE)

1. Introduction

The most common cause of death worldwide is cancer. In cancer treatment, various diagnostic methods are used in clinical studies. The dynamics of cancer cells are studied using mathematical models. These models provide information about different diagnostic methods for treating cancer-related complexities. In cancer patient tumor formation is common. Tumour growth is influenced when cells enter the proliferative state. Treating tumour cells with traditional methods is costly. The traditional cancer treatment methods are less likely to determine the behaviour of the tumour patient in response to therapeutic interventions. The limitations of the traditional model have led to the development of mathematical models (Azizi, 2025). Mathematical models are highly accurate and provide information about patient behaviour and determine the likelihood of improvement in cancer patients in response to treatment. Mathematical models are designed to provide in-depth knowledge about cancer cell proliferation and their molecular structure. A mathematical modelling system allows researchers to predict tumour response under different conditions. Mathematical models are developed to translate biological phenomena into mathematical formulations to improve understanding of the behaviour of cancer cells. Moreover, these computerized mathematical models improve the quality of treatment strategies against tumour growth cells (Debnath et al., 2025). Developing personalized medication through mathematical models is a modern development in the field of biological sciences.

Biomedical processes are studied through mathematical models. These models provide information about biological processes. Computational models help in predicting the progression of tumours in living systems. Through mathematical models, different aspects of cancer cells are studied. Some mathematical models explain the basic biology of cancer cells, whereas others are designed to elucidate the complex structure of cancer cells. Macroscopic models are developed to

study the macroscopic structure of cancer cells. The data provided by these models on cancer cells helps develop anti-cancer therapies. Different researchers made studies on tumour cells using a biomathematical models (Hutton & Hossain-Ibrahim, 2025). A scientist predicted that using a biomathematical model would provide information about the effect of radiation therapy on tumour cells. Two types of mathematical models were used to study the response to radiation therapy in cancer-causing cells. The first model was stochastic and explained the impact of radiation therapy on apoptosis. The second continuum model was used to study the response of GBM to radiation. Additionally, researchers used a third model, a non-stochastic model. This model predicted the kinetics of tumour cells. The third model explained tumour kinetics by providing information on proliferating and dead cancer cells. The volume of tumour cells is also calculated using a mathematical model (Ibrahim, 2025). The volume of tumour cells is estimated through 1-dimensional model. Such 1-dimensional models were developed in 1970.

Tumour cell growth is predicted from the cell proliferation rate. Various models are used to predict cancer cell growth rates. The exponential model explains the unlimited growth rate of tumour cells. Some advanced tumour detection models explain that the growth of tumours depends upon their ability to compete for space. More space means more growth of tumorous cells (Lorenzo et al., 2025). Mathematical models estimate the position of vascular invasion using mathematical equations. The patterns found in agent-based models detect intravascular invasion. Hybrid models are developed to study the microscopic behaviour of tumour cells. All these model frameworks use PDEs to yield outcomes in mathematical form. These models for detecting tumour cell growth dynamics help researchers develop therapies against tumour cells (Moradi Kashkooli et al., 2025). Researchers use mathematical equations to explain each parameter that drives tumour cells' rapid progression.

Treating tumour cells is possible by understanding the parameters that govern tumour growth. These parameters vary among cancer cells. Some cancer cells divide while others proliferate in cells; the structural properties of tumour cells also play a role in determining the nature of the tumour. Benign tumours and malignant tumours are two major types of tumours. In one type, tumour cells spread, whereas in another, they affect neighbouring cells. All the parameters that describe tumour cell behaviour are determined using computational mathematical models. Bayesian methods are used to estimate values obtained from mathematical formulations (Murias-Closas et al., 2025). The reliability of data obtained from mathematical equations depends on the values used. Sensitivity analysis helps in identifying the real data and its results. Additionally, the parameter that directly influences model results is identified through a sensitivity analysis. Developing an accurate and reliable model for estimating tumour growth parameters is challenging. The model's reliability is directly linked to the results. A more reliable model is more likely to yield accurate data that clinical researchers can use. Also, different model types are available for different tumour growth patterns (Ochieng, 2025). Each tumor cell is analyzed by a specific type of computational mathematical model.

Great benefits are observed using bio-mathematical models. This model is inexpensive and yields accurate results within a limited time frame. These models help physicians better understand the structural behaviour of cancer cells. Models allow researchers to test different scenarios and situations without putting patient life at risk. With advances in technology, biomathematical models have evolved. These models use AI and machine learning technology to make their results more reliable and error-free. Developing personalized medicine through computational mathematical models is the modern clinical approach (Sirlanci et al., 2026). Additionally, collecting large datasets using a mathematical model enables scientists to analyze them with high precision. An algorithmic bio-mathematical model provides detailed information on the tumour's size and malignancy. Genetic information about the patient's genome is obtained using mathematical formulations and methodologies. This genomic data helps specialists determine which parts of the patient's genome are affected by tumour-causing cells. The realistic results provided by computational mathematical models make their use common in research laboratories and healthcare sectors. Clinical organizations are using these computational models for early detection of tumour growth cells in patients with different types of cancer (Tóth et al., 2025). Moreover, the health sector is increasingly adopting computational biomathematical models, as these are safer and more widely used than traditional mathematical models. Governments in different countries are making efforts to apply computational techniques in clinical settings to support reliable clinical processes.

1.1 Research Objectives

This research paper explains the importance of computational bio-mathematical models for predicting tumour growth rates. Moreover, tumour growth-related parameters are studied using algorithmic mathematical models.

2. Literature Review

Researchers claim that using computational models helps in understanding the complex tumour growth cells. Computational models analyse large-scale clinical datasets to predict cancer progression accurately. Combining computational mathematical models with informatics systems enhances the overall development of personalised medicine

(Albers et al., 2026). Studies show that computational models provide timely information about cancer cell proliferation in affected patients. This timely information helps in tackling disease progression at an early stage. Treating tumour cells at an early stage reduces the chances of disease progression and severity. Monitoring cancer cells during the growth stage is challenging; these cells are treated immediately after their detection in a patient (Beretta et al., 2026). Studies show that health complications due to PDAC are severe. The tumour growth pattern in PDAC is different from that of other tumours. To determine cell proximity and structure, functional cellular neighbourhoods are employed in research. FunCN results indicate that increased neutrophilic cell interactions in the liver are responsible for the high tumour growth rate in PDAC (Cho et al., 2026). Scholars' studies suggest that the trend toward developing regenerative medicine through computational models is increasing worldwide. Various in vitro and in vivo processes are controlled using a computational modelling system. Cell-cell interactions at the biological level are modelled using a computational scaffold method (García-Gareta & García-Aznar, 2026). Scholars have shown that breast cancer treatment has improved through AI-based therapeutic strategies. Genome profiling is performed using AI in precision oncology. LMICS are unable to develop therapeutic medicines using AI due to the high cost of AI systems in the healthcare sector (Gharthey et al., 2026). Studies indicate that the use of AI in the development of nanomedicines is enhancing the quality of medication production. Drugs are highly selective and are effective only against certain diseases. DDS has enhanced drug selectivity, thereby improving drug efficacy (Habeeb et al., 2026). Scholar's studies declare that the number of breast cancer patients is increasing around the globe. The complexity of this cancer has rendered its treatment process ineffective. Developing anti-cancer therapies through computational methods has improved the effectiveness of these drugs. These drugs, when given to breast cancer patients, show positive outcomes (Kalhor et al., 2026). Studies explain that commotional models improve the bio-signalling processes. Bio-signals, such as ECG, are monitored and analysed using computerised bio-signalling systems. These computerised bio-signalling models employ an algorithmic approach to improve the quality of results obtained from ECG signals (Kumari & Hasija, 2026). Studies reveal that SNIVs are responsible for glioma production and disease progression. The complexity of this disease limits treatment options.

Using an ODE model helps in developing an effective SNIV therapeutic approach. The mathematical model provides information on tumour growth patterns via growth curves. These growth curves serve as a reference for assessing the progression of cancer cells in SNIV (Makam & Dobrovolny, 2026). Studies of personalised treatment processes show that computational techniques have supplanted standardised therapeutic approaches. Psychiatric disorders are treated using modern neurotherapeutic technology. The treatment precision efficiency is thirty to forty percent with traditional therapeutic methods (Mujica-Parodi et al., 2026). Research studies determine that the healthcare sector is facing an extreme burden due to a large number of people being affected by diabetes mellitus. Effective treatment strategies for diabetes mellitus help mitigate the disease worldwide. Assessing disease status using a computational mathematical model is an effective disease management strategy (Nivetha & Ghosh, 2026). Studies indicate that omics research is revolutionising disease prevention strategies. Machine learning is used to improve results from omics research. Genomic expression is studied using data generated by omics research. Genomics studies are conducted at multiple scales using an AI-based gene-expression model (Pălăștea et al., 2026). Scholars' theories suggest that metastasized tumour cells are treated using RRTs. This therapeutic approach is developed using AI tools. The promising impact of RRTs on tumour cell removal makes their use suitable for clinical trials. Optimization of RRTs is possible using computational techniques (Ryhiner et al., 2026). Studies of scholars reveal that cancer cell dynamics are studied using modern computational models. These models are highly specific for detecting complexities of breast-related cancer as well as lung cancer. Additionally, the effects of radiation on cancer cells and its impact on the dynamics of cancer cells are explained using mathematical formulations (Sarma et al., 2026). Moreover, using a computational model for personalized medicine development is a complicated task. All the complexities and challenges related to personalized medicine production are tackled using a machine learning system. A machine learning algorithmic approach minimises the risk of error in data obtained through computational methods and facilitates personalised medicine production (Sirlanci et al., 2026). Studies indicate that FUS is a non-invasive therapeutic technique that destroys cancer cells using thermal ablation. Additionally, tissue structural properties change when heat is applied to cancer cells via FUS therapy. PBTE improves FUS therapy by providing information on the heat distribution pattern in the body (Valencia Narva et al., 2026). Research indicates that the complexity of scientific problems is addressed through computational mathematical models. These models provide real-time solutions and improve decision-making. Moreover, behavioural patterns are identified using AI models (Veeraraghavan, 2026). Studies indicate that the efficacy of immune checkpoint inhibitors varies among patients with cancer. This therapeutic approach is workable only in a few cancer patients.

Mathematical models identify the treatment response of cancer cells. The mathematical model is specifically designed to develop a safer approach to treating deadly cancer cells (Wang et al., 2026). Studies developed to understand cancer cell behaviour suggest that a personalized biophysical brain tumour model is expensive for treating individual cancer patients. The cost of the model limits its use in therapeutic approaches. The personalised biophysical model is replaced

with a neural network to improve understanding of tumour growth rate. The neural network model is more efficient at producing accurate results than the personalised tumour model (Weidner et al., 2026). Scholars declare that the impact of traditional on cells is studied using the radiation biology approach. Computational models indicate that some human organs exhibit high dose-tolerant capacity, whereas others exhibit lower dose-tolerant capacity. The dose-dependence slows the treatment process. Additionally, the response of cancer cells to radiation is a complex phenomenon that requires a computational mathematical model for its understanding (Yusufaly et al., 2026).

3. Methodology

The article is based on a quantitative, computational research design to develop and test bio-mathematical models for predicting tumour evolution. The approach applies mathematical modelling and numerical simulation, and parameter estimation tools to study tumour dynamics over time. A systematic comparison of tumour growth models and an assessment of their forecasting performance on observed data are conducted using a model-based approach.

3.1 Tumour Growth in Mathematical Models

Various biomathematical models have been developed to describe tumour development, including the exponential, logistic, and Gompertz models. Such models rely on ordinary differential equations (ODEs), which describe how the size of the tumour varies with time. All the models make some biological assumptions, including unlimited growth, saturation of growth, and deceleration of growth under environmental constraints. The mathematical equations would provide a theoretical basis towards understanding tumour growth in a range of biological conditions.

3.2 Data Collection and Preparation

To ensure reliability and relevance, tumour growth data are obtained from previously published experimental or clinical studies. The datasets provide time-series data on tumour volume or cell population. Before analysis, the data is pre-processed to remedy inconsistency, missing values, and to standardize measurements, where necessary. This step will ensure compatibility between the empirical data and the computational models.

3.3 The Methods for Calculating Parameters

Model parameters, such as the growth rate and carrying capacity, are numerically optimised. The least-squares estimate is used to minimize the difference between the observed tumour data and the model projections. The computational steps are applied to the parameter values, causing them to change over time to achieve the optimal model fit. Using this approach, one can obtain realistic tumour growth patterns grounded in empirical evidence. Computational simulation and model validation involve using numerical solvers to simulate tumour development over time. The simulated results are juxtaposed with real tumour growth data to assess the models' accuracy. Prediction performance is assessed using goodness-of-fit metrics, such as residual analysis and error measures. A comparative experiment is conducted to determine which model best predicts tumour growth.

3.4 Equational Analysis of Tumour Growth Models

3.4.1 Exponential Growth Model

The exponential model represents unrestricted tumour growth and is commonly used to describe early-stage tumour development. It assumes that the tumour grows at a constant rate without environmental limitations. The governing equation is given by:

$$\frac{dN(t)}{dt} = rN(t)$$

where $N(t)$ denotes tumour size at time t , and r represents the intrinsic growth rate. The analytical solution of this equation is:

$$N(t) = N_0 e^{rt}$$

where N_0 is the initial tumour size. Although simple, this model tends to overestimate tumour growth at later stages because it does not account for biological constraints, such as nutrient limitation or immune responses.

3.4.2 Logistic Growth Model

The logistic model introduces a carrying capacity to represent environmental limitations on tumour growth. It is expressed as:

$$\frac{dN(t)}{dt} = rN(t) \left(1 - \frac{N(t)}{K}\right)$$

where K is the carrying capacity of the tumour environment. The solution of the logistic equation is:

$$N(t) = \frac{K}{1 + \left(\frac{K - N_0}{N_0}\right)e^{-rt}}$$

This model reflects an initial exponential growth phase followed by a slowdown as the tumour approaches its maximum sustainable size.

3.4.3 Gompertz Growth Model

The Gompertz model is widely used in tumour modelling because it describes asymmetric growth deceleration observed in real tumours. The differential equation is defined as:

$$\frac{dN(t)}{dt} = rN(t) \ln \left(\frac{K}{N(t)} \right)$$

where r is the growth constant and K represents the asymptotic tumour size. The solution is given by:

$$N(t) = K \exp [-e^{-rt+C}]$$

where C does the initial condition determine a constant. The Gompertz model captures the gradual reduction in growth rate as the tumour expands.

3.4.4 Parameter Interpretation and Model Comparison

In all models, the parameters r , K , and N_0 play critical roles in defining tumour dynamics. The exponential model is suitable for short-term predictions, while logistic and Gompertz models provide more realistic long-term behaviour. Comparative equational analysis allows identification of the most appropriate model based on tumour stage and available data (Figure 1).




Figure 1: Tumour Growth Prediction

4. Smart PLS Algorithm Model




Figure 2: Smart PLS Algorithm Model

The above figure 2 model represents the smart PLS algorithm for tumour growth prediction, computational modelling, and parameter estimation. The TGP indicates that 0.995, -0.192, and 0.027 are positively and negatively associated with them. The results show that the 99%, 19%, and 2% significance levels differ between them. The results also indicate that CM shows 29% and 91% significant levels, and that the result shows a 16% positive and significant relation between PE and CM. The results indicate a 21% positive and significant association between TGP and PE (Figure 3).




Figure 3: Tumor Boundary Delineation and Predicted Growth Region on MRI Image

5. Descriptive Statistic Analysis

Table 1: Results of Descriptive Statistic Analysis

Name	Mean	Median	Scale Min	Scale Max	Standard Deviation	Excess Kurtosis	Skewness	Cramér-Von Mises P-Value
TGP1	1.680	2.000	1.000	3.000	0.646	-0.662	0.434	0.000
TGP2	1.500	1.000	1.000	3.000	0.574	-0.523	0.653	0.000
TGP3	1.760	2.000	1.000	4.000	0.736	0.279	0.734	0.000
CM1	1.800	2.000	1.000	4.000	0.748	0.040	0.650	0.000
CM2	1.580	1.000	1.000	3.000	0.666	-0.506	0.744	0.000
PE1	1.640	2.000	1.000	3.000	0.686	-0.701	0.622	0.000
PE2	1.780	2.000	1.000	4.000	0.782	-0.241	0.678	0.000
PE3	1.780	2.000	1.000	4.000	0.782	-0.241	0.678	0.000

The above results of table 1 demonstrate that descriptive statistics present the mean values, median rates, minimum and maximum values, and the significance levels for each variable. The TGP1, TGP2, and TGP3 show positive mean values of 1.680, 1.500, and 1.760, respectively. All of them show positive average values. CM1,2 show positive mean values, with rates of 1.800 and 1.580, respectively. The overall result shows that 100% significant level between them. The parameter estimation represents that 1.640 and 1.780 are the mean rates between them (Figure 4).




Figure 4: Comparison of Tumor Growth Predictions: Stable vs. Unstable Computational Model

6. Applications of Biomathematical Tumour Growth Modelling

6.1 Personalized Cancer Treatment Planning

Biomathematical modelling finds extensive uses in personalized cancer treatment planning. Projections of tumour growth based on the patient's individual factors allow the oncologist to customize the treatment. Using tumour volume, growth rate, and proliferation data within computational models, physicians can predict how a patient's tumour will respond to different treatment regimens. As a case in point, the Gompertz model can forecast tumour response to chemotherapy over time, providing details of the appropriate dose schedule and administration frequency. This predictive capability has enabled the development of adaptive medicines, in which treatment strategies are modulated in real time in response to tumour behaviour, minimizing toxicities and maximizing therapeutic response.

6.2 Radiation Optimization

Radiation planning and optimization are crucial to mathematical tumour models. The tumour size, growth rate, and cell cycle dynamics determine the efficiency of radiation therapy. Using computational models, the tumour cells' response to radiation therapy can be simulated, enabling physicians to determine the optimal dose distribution that spares healthy tissues. Logistic and Gompertz models are particularly useful because they can describe growth saturation and reduced proliferation at later stages. By integrating model predictions with imaging data, such as MRI or CT scans, clinicians can organize precision-targeted radiotherapy, thereby enhance outcomes and reduce side effects.

6.3 Therapy Development and Preclinical Testing

Biomathematical models find extensive application in the development of cancer therapy. Experimental and preclinical studies often utilize animal models, which may not be ideal for replicating human tumour behaviour. Prior to clinical trials, computational modelling can predict the efficacy of medicines, dose-response relationships, and treatment regimens in tumour growth by simulating tumour growth under different pharmacological conditions. The method reduces the amount of animal testing required and accelerates drug discovery. Examples include models that forecast tumour shrinkage over time in response to cytotoxic drug treatment and that assess how combination therapy might enhance treatment effectiveness. Sensitivity analysis may assist in identifying the parameters that have the greatest effect on treatment

outcomes, e.g., the proliferation rate or drug clearance.

6.4 Early Detection and Prognostic Assessment

With the help of accurate tumour growth models, it is possible to detect and predict tumour growth early. By incorporating patient-specific data into models, physicians can identify abnormal growth patterns that reflect aggressive malignancies. Gompertz models are usually used in long-term tumour prediction, whereas exponential growth models are used to identify early, rapid growth. Equational models can also be used to compute doubling time, a valuable prognostic marker in oncology. High-risk cancers are detected early enough that intervention can be implemented in time, enabling patients to survive. Computational models may have the potential to forecast tumour recurrence after surgery or treatment and to inform long-term management strategies.

6.5 Overview

This system aids nurses in clinical decisions about chronic pain management with medication. Oncology care is enhanced by integrating tumour growth models into clinical decision support systems (CDSS). When model predictions are combined with patients' medical records, imaging data, and genomic data, CDSS solutions can provide actionable insights. An example of a CDSS might be able to recommend individualized therapy, assess tumour remission risk, or recommend alternative drugs in advance, depending on the tumour's predicted behaviour. The practice reduces subjectivity and promotes evidence-based decision-making in therapeutic practice.

6.6 Tumour Biology

Mathematical modelling provides a theory for studying tumour biology. It allows researchers to simulate the behaviour of tumour cells' interactions with their environment, including nutrient transport, angiogenesis, and the immune system. Models enable the exploration of hypothetical situations, e.g., the consequences of reduced oxygen supply to tumours or the effects of adding a customized immunotherapy. By adjusting model parameters, scientists can explore complex biological processes that are difficult to test experimentally, generating hypotheses that can be tested in the laboratory. This approach enables quantitative assessment of tumour progression and contributes to the development of new treatment options.

6.7 Clinical Trial Predictive Modelling

Models of tumour growth are increasingly used in clinical trials. Controlling computational simulations can provide an approximation of the expected variation in tumour behaviours within a patient cohort, which is useful for sample size and trial period planning. It allows researchers to refine trial protocols by estimating the expected outcomes of different treatment regimens, thereby reducing costs and maximizing efficiency. Moreover, models permit adaptive clinical trials, whereby interim findings are made to alter the study design or dose allocation based on estimated tumour behaviour. This reduces the risk of adverse treatment outcomes and enhances patient safety.

6.8 Combination of Biomarkers with Imaging

Medical imaging and biomarker data are often used to improve prediction accuracy through advanced tumour modelling. MRI, CT, and PET scans offer the spatial and volumetric data. However, growth dynamics can be assessed using biomarkers such as circulating tumour DNA or cell proliferation indices. This information, when combined with computational models, could allow doctors to make spatiotemporal predictions of tumour growth, evaluate therapeutic response and monitor progression in real time. Oncology is supported by superior predictive performance with these individualized integrative approaches.

6.9 Education & Training

Medical education and professional development also employ bio-mathematical tumor modelling. Computational tumour growth models are visual and interactive tools that can represent concepts such as cell proliferation, growth inhibition, and therapeutic response. Oncology trainees and medical students can assess their understanding of tumour biology and decision-making using virtual tumours under varying treatment conditions, without exposing patients to risk.

6.10 Future Projections

AI and ML Fusion. Lastly, machine learning and artificial intelligence can be used to predict tumour development at a higher level by augmenting the available tumour development models. Real-time optimization of model parameters using data is also possible; sophisticated correlations in patient data can be identified, and personalized predictive oncology is

enabled. The hybrid frameworks, which incorporate mechanistic models and use AI, can help revolutionize cancer care by providing dynamically updated patient-specific predictions that inform treatment decisions.

7. Discussion

The application of biomathematical models to predict tumour growth provides a solid basis for cancer prediction and control. Based on the analysis, it is possible to conclude that the various models, including the exponential, logistic, and Gompertz models, have distinct merits and limitations. The exponential model performs well in early-stage tumour development, where the number of environmental constraints is minimal; however, in the late stages, it overestimates growth, and models should be selected based on tumour type. Carrying capacity and growth slowdown are incorporated into logistic and Gompertz models, yielding more biologically realistic results, particularly when the tumour is mature or large. The accuracy of the models' predictions depends on the parameter estimates. The paper reveals that including patient-specific or experimental data enables calibration of growth rate, carrying capacity, and starting tumour size, thereby enhancing the reliability of the models. Nonparametric methods, such as least-squares estimation, that employ computational optimization are used to ensure that the models accurately represent observed tumour dynamics. This underscores the potential of biomathematical methods to improve tailored treatment planning, enabling physicians to forecast tumour responses to medications and the optimal intervention strategy. Models in healthcare decision-making are also emphasized in the discussion.

Spatiotemporal tumour progression predictions derived from tumour growth predictions, imaging, and biomarker measurements can help clinicians with early identification, prognosis, and treatment monitoring. Additionally, predictive modelling enables dynamic treatment processes, thereby reducing the risk of under- or over-treatment. This is because the ability to model potential treatment scenarios provides a non-invasive arena for more effective drug testing, combination therapy testing, and clinical trial design. However, it does not mean that there are no barriers to the widespread adoption of these concepts. Prediction accuracy may be affected by tumour heterogeneity, variation in microenvironmental variables, and a lack of high-quality longitudinal data. In addition, although mechanistic models are accurate in the context of biological processes, they can oversimplify complex associations, such as immune responses, angiogenesis, and metastasis. Integrating a mechanistic model with data-driven approaches, such as machine learning, can enhance model adaptability and predictive power, particularly for tumours that are dynamically changing. Altogether, the discussion points to the idea that biomathematical modelling is not used as a substitute for clinical judgment but rather as a complementary tool to enhance decision-making in oncology. Its application in research, clinical planning, and teaching demonstrates practical and theoretical relevance, aligning with the current trend toward precision and tailored cancer treatment.

8. Conclusion

Tumour growth: Biomathematical modelling. Tumour growth is an effective method for understanding and predicting cancer progression. In this paper, it is demonstrated that models such as the exponential, logistic, and Gompertz offer valuable frameworks for characterizing tumour dynamics across different physiological conditions. Although the exponential model is effective at predicting growth in the early stages, the logistic and Gompertz models are more realistic for advanced-stage tumour growth because they account for environmental limits and deceleration. By integrating computational simulations with parameter estimation methods, it is possible to tune model parameters to patient-specific or experimental data. This enhances predictive power and applies to customized cancer therapy, therapeutic optimization, and prognostic evaluation. Clinicians can determine the effect of therapy, design adaptive therapies, and make informed decisions based on the tumour's expected response by simulating tumour growth under different conditions.

Moreover, modelling, combined with imaging and biomarker data, can be used to track tumour growth over space and time, thereby enhancing early diagnostics and long-term patient monitoring. In addition to applications in clinical practice, bio-mathematical models can serve as a research and educational platform. They facilitate hypothesis testing in tumour biology and drug development, and reduce reliance on costly animal studies, thereby enhancing efficiency. The predictive nature of these models indicates that they can guide the direction of treatment efforts and minimize adverse outcomes. However, the problem of tumour heterogeneity, microenvironmental variability, and insufficient longitudinal data suggests the need for further development. Combining machine learning and artificial intelligence technologies with mechanistic models would help address these limitations and enhance predictive reliability. In summary, biomathematical modelling is an important adjunct to clinical and experimental oncology. It is a crucial component of cancer management in the modern world, providing a quantitative understanding of tumour development, supporting precision therapy, fostering innovative research, and improving patient outcomes.

9. Recommendations

9.1 Incorporating Patient-Specific Data

The Patient-Specific Clinical, Imaging, and Biomarker Data. Modelling programs for future tumour growth must incorporate patient-specific clinical, imaging, and biomarker data. Individualized data enables appropriate calibration of model parameters, thereby enhancing the reliability of predictions. The most important priority for clinicians is the collection of longitudinal tumour data, along with critical biological indicators, so that models reflect tumour dynamics across individuals.

9.2 Selection of the Model depending on the Tumour Characteristics

There is different modelling methods needed in different tumour types and different tumour stages. Simple exponential models can adequately address tumours at an early stage, whereas more complicated or heterogeneous tumours need logistic or Gompertz models. Researchers and clinicians rejecting a model should carefully evaluate tumour properties before making relevant predictions.

9.3 Incorporate the Tumour Growth Models in CDSS to Plan Treatment in Real-Time

This integration enables physicians to simulate therapeutic outcomes, refine dose schedules, and make adaptive treatment decisions, thereby improving patient care and reducing side effects.

9.4 Introducing Machine Learning and AI

Future studies need to keep in mind that hybrid methods, which use mechanistic tumour models along with machine learning, should be considered. AI can aid in parameter estimation, the identification of complex trends, and improved predictive power, particularly in dynamically changing cancers. With this integration, individualized oncology and adaptive treatment options can be improved.

9.5 Standardization and Validation

The modelling processes are to be standardized, and computational predictions are to be compared with an independent clinical or experimental dataset. Strict validation guarantees model stability, repeatability and wide applicability in different tumour types and populations.

9.6 Education and Research Applications

Biomathematical models have the potential to improve medical education and research. Simulation systems help students and researchers explore tumour dynamics, develop hypotheses, and create new treatment methods without exposing patients to harm.

10. References

- Albers, D., Cato, K., Layton, A., & Rossetti, S. C. (2026). Interdisciplinary development and application of computational methods in informatics for clinical applications. In (Vol. 33, pp. 1-6): Oxford University Press.
- Azizi, T. (2025). Mathematical Modelling of Cancer Treatments, Resistance, Optimization. *AppliedMath*, 5(2), 40.
- Beretta, E., Cavaterra, C., Fornoni, M., Lorenzo, G., & Rocca, E. (2026). Iterative Algorithms for the Reconstruction of Early Stages of Prostate Cancer Growth. *Journal of Nonlinear Science*, 36(1), 1-47.
- Cho, Y., Lee, J. W., Shin, S. M., Hernandez, A. G., Yuan, X., Schneider, J., Hooper, J. E., Wood, L. D., Jaffee, E. M., & Deshpande, A. (2026). Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma. *Cancer Immunology Research*.
- Debnath, G., Vasu, B., Gorla, R. S. R., Bég, O. A., & Bég, T. A. (2025). Integrating Mathematical Models in Clinical Oncology: Enhancing Therapeutic Strategies. *Archives of Pharmacology and Therapeutics*, 7(1), 1-27.
- García-Gareta, E., & García-Aznar, J. M. (2026). Computational Modelling of the Mechanobiology of Scaffolds and Their Interaction with Cells and Tissues. In *Contemporary Tissue Engineering and Regenerative Medicine: From Organ Regeneration to Bioengineered Tissue Models* (pp. 247-271). Springer.
- Ghartey, F. N., Anyanful, A., Moore, S. E., Ekor, M., Edzie, E. K. M., Ephraim, R. K., & Zumesew, F. (2026). A Theoretical Framework for Quantifying Tumour Resistance to Standardized Treatments: A Novel Rudimentary Scalar Mathematical

- Model with Implications for Breast Cancer Prognosis and Treatment. *medRxiv*, 2026.2001. 2012.26343951.
- Habeeb, M., Vengateswaran, H. T., You, H. W., Chenchu Lakshmi, K., Pawar, S. S., & Gaikwad, S. D. (2026). Revolutionizing Drug Delivery: The Role of Artificial Intelligence in Nanomedicine and Precision Pharma. In *Applied Artificial Intelligence for Drug Discovery: From Data-Driven Insights to Therapeutic Innovation* (pp. 583-601). Springer.
- Hutton, D. L., & Hossain-Ibrahim, K. (2025). Using Mathematical Models to Predict Glioblastoma Growth and Response to Treatment in a Patient-Specific Manner. In *Modelling and Computational Approaches for Multi-Scale Phenomena in Cancer Research: From Cancer Evolution to Cancer Treatment* (pp. 11-59). World Scientific.
- Ibrahim, B. (2025). Dynamics of spindle assembly and position checkpoints: Integrating molecular mechanisms with computational models. *Computational and structural biotechnology journal*.
- Kalhor, S., Irajizad, A., & Ahmadi Seyedkhani, S. (2026). Computational Techniques to Design Drugs for Breast Cancer Treatment: From Quantum Mechanics to Molecular Dynamics. In *Nano Theragnostics in Breast Cancer: Advances, Challenges, and Future Prospects* (pp. 291-329). Springer.
- Kumari, N., & Hasija, Y. (2026). Computational methods for biosignal processing: Modeling and control. In *Medical Robotics and Intelligent Healthcare Technologies* (pp. 139-164). Elsevier.
- Lorenzo, G., Hormuth, D. A., Wu, C., Pash, G., Chaudhuri, A., Lima, E. A., Okereke, L. C., Patel, R., Willcox, K., & Yankeelov, T. E. (2025). Validating the predictions of mathematical models describing tumor growth and treatment response. *ArXiv*, arXiv: 2502.19333 v19331.
- Makam, S., & Dobrovolny, H. M. (2026). Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma. *CPT: Pharmacometrics & Systems Pharmacology*, 15(2), e70205.
- Moradi Kashkooli, F., Mirala, F., HH Tehrani, M., Alirahimi, M., Souri, M., Golzaryan, A., Kar, S., & Soltani, M. (2025). Mechanical Forces in Tumor Growth and Treatment: Perspectives From Biology, Physics, Engineering, and Mathematical Modeling. *WIREs Mechanisms of Disease*, 17(2), e70000.
- Mujica-Parodi, L. R., Öngür, D., & Richardson, R. M. (2026). Opportunities and Challenges in Precision Neurotherapeutics. *Annual Review of Biomedical Engineering*, 28.
- Murias-Closas, A., Prats, C., Calvo, G., López-Codina, D., & Olesi, E. (2025). Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions. *Ebiomedicine*, 113.
- Nivetha, S., & Ghosh, M. (2026). Mathematical modeling and cost-effective intervention strategies for diabetes management: A data-driven and numerical analysis approach. *PloS one*, 21(1), e0339463.
- Ochieng, F. O. (2025). Computational Modeling of Tumor Dynamics Incorporating Drug Resistance and Immune Response for Optimized Cancer Treatment. *International Journal of Applied and Computational Mathematics*, 11(2), 62.
- Pălăștea, E. A., Matache, I.-M., Radu, E., Henegariu, O., & Bucur, O. (2026). AI-Based Prediction of Gene Expression in Single-Cell and Multiscale Genomics and Transcriptomics. *International Journal of Molecular Sciences*, 27(2), 801.
- Ryhiner, M., Song, Y., Saboury, B., Glatting, G., Rahmim, A., & Shi, K. (2026). Mathematical and computational nuclear oncology: toward optimized radiopharmaceutical therapy via digital twins. *PET clinics*, 21(1), 117-131.
- Sarma, B., Dutta, H., & Das, U. (2026). Fractional-order modelling of cancer cell population dynamics affected by radiation. *Computational Biology and Chemistry*, 108924.
- Sirlanci, M., Albers, D., Kwak, J., Smith, C., Bennett, T. D., & Bair, S. M. (2026). Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling. *Journal of the American Medical Informatics Association*, 33(1), 242-251.
- Tóth, B., Guerrero-Bustamante, O., Murillo, M., Duque, J., & Polo-Mendoza, R. (2025). Development of Mathematical and Computational Models for Predicting Agricultural Soil–Water Management Properties (ASWMPs) to Optimize Intelligent Irrigation Systems and Enhance Crop Resilience. *Agronomy*, 15(4), 942.
- Valencia Narva, C., Payne, A., & Dillon, C. R. (2026). Integrating temperature-dependent tissue properties into focused ultrasound computational models for enhanced treatment planning. *International Journal of Hyperthermia*, 43(1), 2606701.

- Veeraraghavan, V. (2026). Mathematical Approaches of Artificial Intelligence (ML) in Behavioral, Health. *AI and ML in Behavioral, Health, and Applied Sciences*, 165.
- Wang, Y., Bergman, D. R., Trujillo, E., Ziblat, A., Fernald, A. A., Li, L., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2026). Enhancing Predictive Accuracy in Immunotherapy Models through Data Integration and Parameter Identifiability. *bioRxiv*, 2026.2001. 2012.699041.
- Weidner, J., Zimmer, L., Ezhov, I., Balcerak, M., Menze, B., Rueckert, D., & Wiestler, B. (2026). Brain Tumor Growth Inversion via Differentiable Neural Surrogates. *Medical Imaging with Deep Learning*,
- Yusufaly, T., Abdollahi, H., Saboury, B., & Rahmim, A. (2026). Quantitative and Computational Radiobiology for Precision Radiopharmaceutical Therapies. *PET clinics*, 21(1), 133-142.